Goldman Sachs analyst Matthew Sykes downgraded Cytek Biosciences Inc (NASDAQ:CTKB) stock rating from Buy to Sell and reduced the price target to $4.50 from the previous $7.00. The downgrade reflects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback